ORGO Key Statistics, Chart & Performance
The current stock price of ORGO is 3.665 USD. In the past month the price decreased by -28.08%. In the past year, price increased by 13.47%.
ORGO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ORGO. When comparing the yearly performance of all stocks, ORGO turns out to be only a medium performer in the overall market: it outperformed 50.06% of all stocks.
ORGO Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ORGO. ORGO has an average financial health and profitability rating.
ORGO Financial Highlights
Over the last trailing twelve months ORGO reported a non-GAAP Earnings per Share(EPS) of 0.01. The EPS decreased by -90.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.63% | ||
| ROE | -3.47% | ||
| Debt/Equity | 0.01 |
ORGO Forecast & Estimates
8 analysts have analysed ORGO and the average price target is 8.67 USD. This implies a price increase of 136.56% is expected in the next year compared to the current price of 3.665.
For the next year, analysts expect an EPS growth of -58% and a revenue growth 9.76% for ORGO
ORGO Ownership
ORGO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.58 | 377.20B | ||
| AMGN | AMGEN INC | 15.04 | 177.12B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.29 | 111.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.34 | 77.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 688.33 | 46.38B | ||
| INSM | INSMED INC | N/A | 34.49B | ||
| NTRA | NATERA INC | N/A | 32.00B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.37B | ||
| INCY | INCYTE CORP | 15.97 | 20.12B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About ORGO
Company Profile
Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company is headquartered in Canton, Massachusetts and currently employs 869 full-time employees. The company went IPO on 2016-12-02. The company offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
Company Info
ORGANOGENESIS HOLDINGS INC
85 Dan Rd
Canton MASSACHUSETTS 02021 US
CEO: Gary S. Gillheeney Sr.
Employees: 869
Phone: 17815750775
ORGANOGENESIS HOLDINGS INC / ORGO FAQ
Can you describe the business of ORGANOGENESIS HOLDINGS INC?
Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company is headquartered in Canton, Massachusetts and currently employs 869 full-time employees. The company went IPO on 2016-12-02. The company offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
Can you provide the latest stock price for ORGANOGENESIS HOLDINGS INC?
The current stock price of ORGO is 3.665 USD. The price decreased by -3.3% in the last trading session.
Does ORGO stock pay dividends?
ORGO does not pay a dividend.
How is the ChartMill rating for ORGANOGENESIS HOLDINGS INC?
ORGO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about ORGANOGENESIS HOLDINGS INC (ORGO) stock?
8 analysts have analysed ORGO and the average price target is 8.67 USD. This implies a price increase of 136.56% is expected in the next year compared to the current price of 3.665.
Can you provide the market cap for ORGANOGENESIS HOLDINGS INC?
ORGANOGENESIS HOLDINGS INC (ORGO) has a market capitalization of 465.13M USD. This makes ORGO a Small Cap stock.
Can you provide the ownership details for ORGO stock?
You can find the ownership structure of ORGANOGENESIS HOLDINGS INC (ORGO) on the Ownership tab.